Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2007

View Archived Issues

Preclinical and clinical studies on Rebif(R) new formulation

Recent patents disclose new agents for depression, anxiety, psychosis and sleep disorders

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

New therapeutic agents for respiratory and allergic disorders disclosed in recent patents

Novartis invests in Adenosine Therapeutics

Health Canada approves once-daily tramadol

Merck Serono and Ambrx collaborate on growth hormone products

OSI Pharmaceuticals begins phase I trials of OSI-906 for tumors

Recent Janssen and Pfizer patents describe novel analgesic agents

Rylomine significantly reduces postsurgical orthopedic pain

Interim findings for AVN-944 in hematologic malignancies

Kaken and Sunstar sign agreement for bFGF dental product development

NOP receptor antagonist improves parkinsonian-related motor dysfunction

New preclinical data on short-acting sedative CNS-7056

Liraglutide provides better glucose control than insulin glargine in phase III study

Phosphagenics delivery technology shows promise in dermatological fields

EULAR 2007: Studies of certolizumab pegol in rheumatoid arthritis

ARRY-797 meets endpoints in phase I study

ZymoGenetics and Bayer collaborate in global development of rThrombin

FDA agrees on SPA for OxyADF phase III trial

Bayer Schering Pharma to license imaging agent from Avid

DeveloGen grants worldwide exclusive license to Teva for protein kinase B

Resverlogix and Sun Health Research Institute collaborate for treatment of AD

Genzyme seeks FDA approval of Synvisc-One

Inulin polysulfate in vitro studies indicate potential to prevent osteoarthritis progression

Approvable letter for Risperdal sNDAs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...